Genmab — November 2022
-
Today, the Company announced it is increasing its ex-U.S. peak annual net sales expectations for TEPEZZA to greater than $1 billion from the previous estimate of greater than $500 million, following further assessment of the ex-U.S. TED market opportunity and now also incorporating plans to launch TEPEZZA in Europe. The Company continues to expect U.S. peak annual net sales of greater than $3 billion, bringing global peak annual net sales expectations to greater than $4 billion.
-
-
GEN1056 starts recruiting. that is fast. in Moldova... https://clinicaltrials.gov/ct2/history/NCT05586321?A=1&B=2&C=merged#StudyPageTop
-
USA/lukning: Powell sendte aktierne i dørken efter kortvarigt plus https://www.proinvestor.com/investornyt/899194/usa-lukning-powell-sendte-aktierne-i-dorken-efter-kortvarigt-plus
-
Godmorgen
-
Godmorgen
-
Dagens mange regnskaber: https://www.proinvestor.com/finanskalender
-
Although it fell short of response rates shown by its Car-T cell competitors the US approval of J&J ,s Tecvayli on tuesday along with some winning attributes has set it up as a major player in the multiple myeloma treatment paradigm according to key opinion leaders in the field
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind